Galderma Unveils ‘Wake Up To Restylane’, Underscoring Restylane as the Ideal Hyaluronic Acid Treatment for Always-On Natural Beauty
29.1.2026 08:00:00 EET | Business Wire | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, has launched ‘Wake Up To Restylane’, a global campaign that showcases Restylane as an everyday beauty ally. Aligned with the growing desire for effortless, authentic results that restore facial balance and improve skin quality, the campaign highlights Restylane’s unique ability to deliver personalized results that move naturally with expressions to help people look and feel good.1,6,12-18
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260128829353/en/
The launch was unveiled at the IMCAS World Congress 2026 in Paris, where Galderma also presented new clinical data reinforcing Restylane’s efficacy across key facial areas such as the chin, jawline, temples, as well as the décolletage, underscoring its unique position as the only HA portfolio offering a variety of formulations for tailored outcomes.1,8-11
“What's compelling about ‘Wake Up To Restylane’ is its focus on beauty that’s ready when you are. Patients increasingly want treatments that fit seamlessly into their lives, and this campaign captures that shift perfectly. For practitioners, Restylane continues to set the benchmark for HA treatments and remains an indispensable tool in modern aesthetic practice thanks to its proven science, unmatched versatility and reliability, and personalized, natural-looking results.” DR. KULDEEP MINOCHA AESTHETIC PHYSICIAN L’ART BY DR M |
As HA treatments remain the go-to for modern beauty, Restylane helps people wake up ready to go
‘Wake Up To Restylane’ captures a growing desire to look subtly refreshed – like you slept well – without the effort, especially towards beauty-conscious consumers, some of whom might be new to injectables, and want results that look authentic and harmonious, while aligning with their lifestyles. Restylane delivers what skincare and makeup alone can’t: structure, definition, balance, and a lasting glow, thanks to its unique HA that works in sync with your skin.1,6,12-18
Insights from Galderma’s research of over 4,300 consumers and healthcare professionals (HCPs) across four countries (Brazil, China, Germany and the United States) highlight the relevance of this campaign.12 HA treatments remain an important aesthetic treatment option, with about a third of consumers ranking HA as their top injectable choice ahead of neuromodulators.12 HA treatments remain among the most planned procedures globally, which signals the durable relevance and trust in the category.12
HAs are often chosen for deeply personal reasons: people describe HA treatments as an act of self‑care and self‑love, a little indulgence in a stressful life that helps them feel comfortable in their own skin.12 Many are choosing HA specifically to improve skin quality, seeking healthy, glowing, hydrated skin that looks refreshed.12 Patients and practitioners align on natural‑looking results, delivered safely and with reliable outcomes.12 This aligns perfectly with Restylane’s promise: authentic beauty that’s ready when you are, supported by three decades of safety data.1-3
“Restylane has an iconic heritage as a trusted, science-backed HA treatment, and ‘Wake Up To Restylane’ is an exciting evolution in how we connect the brand with evolving beauty aspirations. We’re not just responding to change – we’re leading it – driving the category forward, including for those taking their first steps into aesthetics, while staying true to the authentic always-on beauty and personalization that define the brand." GERRY MUHLE HEAD OF GLOBAL PRODUCT STRATEGY GALDERMA |
Restylane: Backed by science and designed differently, with proven versatility across facial areas and skin concerns
The versatile portfolio of Restylane HA treatments is designed to meet diverse patient needs across key areas of the face and décolletage, from soft, flexible formulations that smooth facial lines and wrinkles for a more youthful look, to firmer gels that provide contouring and structural support.2,5-11,13-21
Ongoing clinical evidence continues to reinforce Restylane’s ability to deliver natural-looking, long-lasting results across multiple indications.8-11 New clinical data presented at IMCAS demonstrated the efficacy of Restylane Shaype™ in shaping the chin, Restylane Lyft™ in improving jawline definition, and Restylane Volyme™ in correcting hollowing of the temples, while Restylane Skinboosters™ improved skin quality and smoothed wrinkles in the décolletage – an area often affected by sleep lines.8-11
With over 30 years of innovation and more than 77 million treatments administered worldwide, Restylane remains highly relevant in addressing some of today’s most significant aesthetic trends and needs, from facial changes following medication-driven weight loss to growing concerns related to menopause and skin health.1,22-24 Galderma’s continued innovation underscores its commitment to helping people feel good in their skin at every life stage.
About the Restylane portfolio
Restylane hyaluronic acid (HA) treatments are designed differently to go beyond volumizing for natural-looking results.1,25-27 Our HA is minimally modified and our innovative manufacturing process preserves its biocompatibility while creating individual products designed for a specific purpose.12,28-30 Powered by NASHA®, NASHA HD™, OBT™ and SB-NASHA™ technologies, Restylane offers gels with the highest firmness to the highest flexibility, enabling personalized treatments that deliver structural support, natural-looking results, and a healthy glow.4-7 Trusted for almost three decades, our HA gels work in sync with your skin for 100% natural-looking results.1-3
About Galderma
Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.
References
- Di Gregorio C, et al. 25+ years of experience with the Restylane portfolio of injectable HA fillers for facial aesthetic treatment. E-poster presented at AMWC; March 27-29, 2024; Monaco.
- Solish N, et al. Dynamics of HA fillers formulated to maintain natural facial expression. J Cosmet Dermatol. 2019;18(3):738-746. doi: 10.1111/jocd.12961.
- Philipp‐Dormston WG, et al. Perceived naturalness of facial expression after HA filler injection in nasolabial folds and lower face. J Cosmet Dermatol. 2020;19(7):1600-1606. doi: 10.1111/jocd.13205.
- Galderma Data on file. MA-56724. X-strain and G’ including Shaype.
- Nikolis A, et al. Effectiveness and Safety of a New Hyaluronic Acid Injectable for Augmentation and Correction of Chin Retrusion. J Drugs Dermatol. 2024;23(4):255–261. doi: 10.36849/JDD.8145.
- Öhrlund Å et al. Differentiation of NASHA and OBT Hyaluronic Acid Gels According to Strength, Flexibility, and Associated Clinical Significance. J Drugs Dermatol. 2024;23(1):1332–1336. doi: 10.36849/JDD.7648.
- Belmontesi M et al. Injectable Non-Animal Stabilized Hyaluronic Acid as a Skin Quality Booster: An Expert Panel Consensus. J Drugs Dermatol. 2018;17(1):83–88.
- Nikolis A, et al. A new NASHA-HD, high G’ hyaluronic acid (HA) injectable evaluated for chin treatment in combination with lower face and mid-face HA filler treatment. Poster presented at IMCAS 2026; January 29-31, 2026; Paris, France.
- Rivers J, et al. Effectiveness and safety of Restylane® Lyft™ Lidocaine for jaw-line definition: A 12-month randomized controlled study. Poster presented at IMCAS 2026; January 29-31, 2026; Paris, France.
- Moradi A, et al. Effectiveness and safety of a hyaluronic acid skin quality injectable for the correction of wrinkles in the décolletage area. Poster presented at IMCAS 2026; January 29-31, 2026; Paris, France.
- Nestor, M. Safety and effectiveness of an OBT™ hyaluronic acid filler for temple hollowing treatment: a randomized, controlled, clinical investigation. Poster presented at IMCAS 2026; January 29-31, 2026; Paris, France.
- Galderma. Data on file. Global report: Aesthetics treatments and hyaluronic acid injectables. Consumers & HCPs. 2025.
- Restylane® Shaype™. IFU. August 2023. Available online. Accessed January 2026.
- Restylane® Lyft™. IFU. August 2023. Available online. Accessed January 2026.
- Restylane®. IFU. August 2023. Available online. Accessed January 2026.
- Restylane® Eyelight™. IFU. August 2023. Available online. Accessed January 2026.
- Lee BM, et al. Rejuvenating Effects of Facial Hydrofilling using Restylane Vital. Arch Plast Surg. 2015;42(3):282–287. doi: 10.5999/aps.2015.42.3.282.
- Distante F, et al. Stabilized hyaluronic acid of non-animal origin for rejuvenating the skin of the upper arm. Dermatol Surg. 2009;35(S)1:389-394. doi: 10.1111/j.1524-4725.2008.01051.x.
- Hilton S, et al. Randomized, Evaluator-Blinded Study Comparing Safety and Effect of Two Hyaluronic Acid Gels for Lips Enhancement. Dermatol Surg. 2018;44(2):261–269. doi: 10.1097/DSS.0000000000001282.
- Restylane® Skinboosters Vital Lidocaine™. IFU. August 2022. Available online. Accessed January 2026.
- Restylane® Skinboosters Vital Light Lidocaine™. IFU. August 2021. Available online. Accessed January 2026.
- Galderma. Data on file. MA-57232 [Updated]. 77 Million treated.
- Fabi SG, et al. The potential role of biostimulators/dermal fillers to address menopause-related skin conditions. Poster presented at IMCAS 2026; January 29-31, 2026; Paris, France.
- Lorenc ZP, et al. Synergistic Efficacy and Safety of Poly-L-Lactic Acid Biostimulator and Hyaluronic Acid Filler for Facial Fullness post Weight Loss due to Glucagon-like Peptide-1 Receptor Agonist Medication. Presented at the ASDS 2025 Annual Meeting; November 13-16; Chicago, United States.
- Restylane. U.S. Instructions for use. Available online. Accessed January 2026.
- Nikolis A, Enright KM, Lazarova D, et al. The role of clinical examination in midface volume correction using hyaluronic acid fillers: should patients be stratified by skin thickness? Aesthet Surg J Open Forum. 2020;2(1):1–12. doi: 10.1093/asjof/ojaa005.
- Talarico S, et al. High patient satisfaction of a HA filler producing enduring full-facial volume restoration: an 18- month open multicenter study. Dermatol Surg. 2015;41:1361–1369. doi: 10.1097/DSS.0000000000000549.
- Edsman K, et al. Gel properties of hyaluronic acid dermal fillers. Dermatol Surg. 2012;38:1170–1179. doi: 10.1111/j.1524-4725.2012.02472.x.
- Galderma. Data on file. MA-58650. Degree of modification of HA fillers.
- Seo K. Facial volumization with fillers. Springer. 2021;29–83. doi: 10.1007/978-981-33-6212-3_2.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260128829353/en/
Contacts
For further information:
Christian Marcoux, M.Sc.
Chief Communications Officer
christian.marcoux@galderma.com
+41 76 315 26 50
Richard Harbinson
Corporate Communications Director
richard.harbinson@galderma.com
+41 76 210 60 62
Céline Buguet
Franchises and R&D Communications Director
celine.buguet@galderma.com
+41 76 249 90 87
Emil Ivanov
Head of Strategy, Investor Relations, and ESG
emil.ivanov@galderma.com
+41 21 642 78 12
Jessica Cohen
Investor Relations and Strategy Director
jessica.cohen@galderma.com
+41 21 642 76 43
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Elliptic Secures $120 Million Investment From Nasdaq Ventures, Deutsche Bank, One Peak and the British Business Bank12.5.2026 17:05:00 EEST | Press release
Elliptic, the global leader in digital asset decisioning, today announced the closing of a $120 million Series D fundraise led by One Peak, with participation from Nasdaq Ventures, Deutsche Bank and the British Business Bank. The round values Elliptic at $670 million. These investors are among the most consequential institutions in global finance, together responsible for trillions in daily market activity, and they have placed their confidence in Elliptic. It is a signal about where the financial system is heading and who is trusted to underpin it, with Elliptic screening more of the global on-chain economy than any other private sector provider. The fundraise will accelerate Elliptic's mission to deliver the enterprise-grade on-chain analytics for the world's largest and most demanding banks, fintechs, government agencies and crypto and payments companies in the world. “As digital assets become more embedded in the global financial system, institutions need trusted infrastructure to
Rigaku Accelerates Next-generation Semiconductor Metrology Development Leveraging World-Class Research Infrastructure12.5.2026 17:00:00 EEST | Press release
Rigaku Corporation, a global solution partner in X-ray analytical systems and a group company of Rigaku Holdings Corporation (headquarters: Akishima, Tokyo; CEO: Jun Kawakami; “Rigaku”), announced the expansion of its development of metrology technologies for next-generation semiconductors, leveraging global research environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260512888328/en/ Signing ceremony with imec held on April 9 As part of this initiative, Rigaku is working with imec, a world-leading semiconductor research and innovation hub headquartered in Belgium, under a three-year development program. Through this effort, Rigaku will advance its core X-ray technologies, including 3D device metrology, high-sensitivity detection of ultrathin films and trace elements, and non-destructive inspection of microscopic defects. As semiconductor devices evolve toward advanced architectures such as Gate-All-Around (GAA) and
Aster Guardians Global Nursing Award Announces Top 10 Finalists for 202612.5.2026 16:54:00 EEST | Press release
On the occasion of International Nurses Day, Aster DM Healthcare has announced the Top 10 finalists for the fifth edition of the Aster Guardians Global Nursing Award 2026, selected from over 134,000 registrations across 214* countries and economies. One of the Top 10 finalists will be honoured with the grand title and a prize of USD 250,000. Aster has appointed Ernst & Young LLP as the 'Process Advisors' of the award. EY has defined a three-stage evaluation process to determine the finalists and the winner. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260512872373/en/ Aster Guardians Global Nursing Awards 2026 - Top 10 Finalists (Photo: AETOSWire) The top 10 finalists for 2026 includes: Dr. Agimol Pradeep (United Kingdom), Dr. Aidah Alkaissi (Sweden), Dinah Sevilla (The Kingdom of Saudi Arabia), Dr. Hammoda Abu-Odah (Hong Kong SAR, China), Hindumbi Kaurom Kakkada (India), Johana Patricia Galvan Barrios (Colombia), Josephin
Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association (EHA) 2026 Congress12.5.2026 16:30:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced that data from key programs in its Hematology and Oncology franchises will be presented at the European Hematology Association (EHA) 2026 Congress, to be held June 11 - 14, 2026, in Stockholm, Sweden. “The breadth of the data that will be showcased at the 2026 EHA Congress highlights the continued advancement of our Hematology and Oncology pipeline and our focus on delivering differentiated medicines for patients with cancer and hematologic diseases,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “These presentations include findings from the frontMIND study, which support the U.S. and EU regulatory applications for tafasitamab (Monjuvi®/Minjuvi®) in patients with first-line diffuse large B-cell lymphoma (DLBCL). Additionally, data presentations for INCA033989, which support our Phase 3 trials, demonstrate the steady advancement of this molecularly targeted therapy that has the potential to revolutionize
Lenovo Enables One-Week Deployment of Production-Ready Agentic AI to Transform Enterprise Workflows12.5.2026 16:00:00 EEST | Press release
Lenovo is enabling enterprises to deploy production-ready, agentic AI solutions in as little as one week1, eliminating the long development cycles that typically delay AI from reaching production, while maintaining enterprise-grade security, governance, and control. This is not theoretical, independent analysis from Signal65 confirms these results in real-world deployments. Lenovo’s Knowledge Super Agent reduced time spent on knowledge-related tasks by 30%, saving up to 120 hours per employee annually. In multiple deployments, organizations reached production up to 24× faster than with custom-built approaches, demonstrating how faster, secure deployment translates directly into faster business outcomes. These results reflect faster deployment and more efficient AI utilization, where each interaction delivers measurable business value. Delivered through the Lenovo AI Library as part of Lenovo Hybrid AI Advantage™, this approach allows organizations to move directly from pilot to operati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom